drugdevelopment News & Analysis
2 articles
Market Mood
Palvella (PVLA) Completes FDA Pre-NDA Meeting for Rapamycin Gel
Palvella Therapeutics (PVLA) has completed a pre-New Drug Application (pre-NDA) meeting with the FDA concerning its rapamycin gel. This meeting allows the company to align on the data needed for the NDA submission, marking a significant step in the drug development process. Successful completion of the NDA could lead to improved market positioning for Palvella in the dermatology sector. The outcome of the NDA will be closely monitored by investors, as it can impact the company's stock performance.
Read More
Eli Lilly and Insilico Partner on AI Drug Development Deal Valued at $2.75B
Eli Lilly has signed a collaboration agreement with Insilico Medicine, valued at up to $2.75 billion, to develop AI-powered drugs for the global market. This partnership extends Lilly's use of Insilico's artificial intelligence technology in drug discovery, potentially accelerating the development of innovative treatments. This deal highlights the growing integration of AI in pharmaceuticals. The financial details include milestones and deeper collaboration efforts that signal a significant commitment to advancing drug discovery methodologies.
Read More